Overview of Molecular Quantification of the BCR-ABL Oncogene in CML Patients

Chronic myeloid leukemia (CML) is considered a common blood cancers and accounts for approximately 15–20% of the total cases leukemia. Recent studies indicated that above 95% patients suffering CML have been found with distinctive Philadelphia chromosome originates from mutual translocation between both arms chromosomes 9 22. During this mutation ABL gene located on get transferred to breakpoint cluster region (BCR) 22 as an effect joined BCR-ABL gene. Furthermore, oncogene characteristically in CML, causing cells divide uncontrollably inducing severe consequences among patients. In line this, applying quantification technique using molecular approaches crucial patient controlling, initiation proper treatment, measurement response therapy, prediction relapse. Of greater significance, assay monitoring quantitative RT-PCR provides physicians essential diagnostic prognostic information.